Please login to the form below
CAR therapies
This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.
Dragonfly signs Celgene as partner for NK cell platform
That differentiates TriNKETs from other immuno-oncology approaches such as checkpoint inhibitors and CAR-T therapies which work through the adaptive immune response only, says the Cambridge, Masachusetts-based biotech. ... Foremost among these was its
Latest news
-
Industry frustrated by late warning on 'no deal' Brexit disruption
One reason stockpiling isn’t a complete solution is that many medicines – such as the new CAR-T therapies - have a very short shelf-life, and cannot simply be stored in
-
CAR-Ts take centre stage as ASH18 comes to a close
The last few days of the American Society of Haematology (ASH) annual congress saw a series of new trials on CAR-T therapies that reinforce the emerging role of this type ... There was plenty more activity on the anti-BCMA CAR-T front at ASH.
-
ASH18: CAR-T and drugs give new options for multiple myeloma
There will be plenty of additional news on CAR-T therapies for myeloma at ASH this year. ... five complete responses in five patients – that could pose a threat to the BCMA-targeting CAR-Ts.
-
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake
CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced yesterday.
-
Digital tech from Autolus and Oxford BioMedica to speed advanced therapies
Also receiving funding is Oxford BioMedica, one of the UK’s leading manufacturers of cell and gene therapies, best know for supplying the lentiviral vector used in Novartis’ CAR-T therapy ... The first ever CAR-T therapies, Novartis’ Kymriah and
More from news
Approximately 1 fully matching, plus 46 partially matching documents found.
Latest Intelligence
-
New models of NHS care – new models of pharma response?
Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available. ... CAR-T therapies are cost-effective for these patients,
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Diagnosis. As with many new rare disease therapies, one of the biggest challenges for Alnylam is to bring as many patients as possible to diagnosis and then treatment. ... therapies, such as CAR-Ts Kymriah and Yescarta.
-
Cancer immunotherapy: What's on the horizon?
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... molecular defects that are driving its
-
30 Women Leaders in UK Healthcare
Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines.
-
The good, the bad and the ugly
The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest appointments
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Download our infographic: Addressing the biggest challenges for rare disease communities
Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
-
Training the next generation of biotech leaders
In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality, with companies in the
-
Addressing the biggest challenges for rare disease communities
year, we saw landmark breakthroughs in advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
-
Ashfield
Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies. ... Whether we’re buying something as simple as a toaster or as expensive as a new car, we’ve all come to expect fantastic service at
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
-
Account Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical (Scientific) Director
-
£120, 000 benefits
- Business Development Director – Health Education
-
excellent commission
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
- Principal Health Economist - North-West
-
Negotiable
- Account Manager- Healthcare Advertising
-
Negotiable
-
Business Director
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
-
Associate Director
-
£75, 000-90, 000
-
Account Manager
-
Negotiable
Subscribe to our email news alerts
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- AstraZeneca’s oncology renaissance
- Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
- Navigating the antibiotic resistance crisis
- Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
- Combined immunotherapies – potential and pitfalls
- ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Quick links
Infographics
